CAI Q2 2021 Earnings — Caris Life Sciences, Inc. Revenue & Financial Results | Market Cap Arena

CAICaris Life Sciences, Inc.

$5B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$86M+13.2% YoY

Gross Profit

$43M50.0% margin

Operating Income

$51M59.3% margin

Net Income

$38M44.3% margin

EPS (Diluted)

$2.17

QoQ Revenue Growth

+6.1%

Cash Flow

Operating Cash Flow

$86M

Free Cash Flow

-$19M

Stock-Based Comp.

$593,000

Balance Sheet

Total Assets

$3.0B

Total Liabilities

$2.2B

Stockholders' Equity

$756M

Cash & Equivalents

$39M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$86M	$76M	+13.2%
Gross Profit	$43M	$47M	-8.6%
Operating Income	$51M	$33M	+54.0%
Net Income	$38M	-$626,000	+6161.2%